Date: 2014-07-10
Type of information: Product acquisition
Compound: Restylane®, Perlane®, Emervel®, Dysport®, Sculptra®
Company: Nestlé (Switzerland) Valeant Pharmaceuticals (Canada)
Therapeutic area: Aesthetic medicine - Dermatological diseases
Type agreement: product acquisition
Action mechanism:
Disease:
Details: *On May 28, 2014, Nestlé announced it will reinforce Nestlé Skin Health with the acquisition from the Canadian firm Valeant Pharmaceuticals International of the full rights to commercialise several key aesthetic dermatology products in the US and Canada for $ 1.4 billion in cash. The two markets together represent more than half of the fast-growing medical aesthetics market around the world. Galderma already commercialises the products included in this transaction outside those markets. Nestlé is acquiring the full rights to commercialise in the US and Canada Restylane®, Perlane® and Emervel®, products used for corrective facial aesthetic treatments, and Dysport®, an aesthetic dermatology treatment. It will also acquire the full rights to Sculptra®, a unique treatment for aesthetic and medical uses in the US, Canada and many markets around the world. Last February,Nestlé announced it would extend its activities to include the field of specialised medical skin treatments through the creation of Nestlé Skin Health S.A., a global leader focused on meeting the world’s increasing skin health needs with a broad range of innovative and scientifically-proven products. The foundation for the company would be Galderma, the 50/50 joint venture with L’Oréal, which would become fully-owned by Nestlé. Bübchen, its existing infant skincare business would be merged into the new entity.
Financial terms: Nestlé acquired the full rights to commercialise these aesthetic dermatology products in the US and Canada for $ 1.4 billion in cash.
Latest news: * On July 10, 2014, as a result of the successful conclusion of the regulatory process and customary closing conditions, Nestlé completed its acquisition of Valeant Pharmaceuticals International’s commercialisation rights to several key injectable aesthetic dermatology products in the US and Canada, as announced on 28 May 2014. These rights will be integrated into Nestlé Skin Health and commercialised by Galderma.
